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Marked susceptibility of South African Helicobacter pylori 
strains to ciprofloxacin and amoxicillin: Clinical implications
Nicoline F Tanih, Benjamin I Okeleye, Nathan Naidoo, Anna M Clarke, Noxolo Mkwetshana, Ezekiel Green, Lucy M Ndip, 
Roland N Ndip
Helicobacter pylori is the principal species of the genus 
Helicobacter that inhabits the gastric mucosa of the human 
stomach. It chronically infects billions of people worldwide1,2 
and causes one of the most frequent chronic bacterial 
infections, involving more than 50% of the world’s population.3 
H. pylori is one of the most genetically diverse of bacterial 
species, and is a major cause of at least 90% of duodenal ulcers, 
70% of gastric ulcers, non-ulcer dyspepsia, gastro-oesophageal 
reflux disease, adenocarcinoma of the distal stomach and 
mucosa-associated lymphoid tissue (MALT) lymphoma in 
many societies.4
H. pylori infection presents a unique therapeutic challenge. 
Determining the optimal treatment is difficult because the 
organism lives in an environment not easily accessible to many 
medications. Several antibiotic agents are used worldwide 
to treat these infections; despite this range of antibiotics, 
the problem of drug resistance to most of them is well 
established.2,5
Reliable treatment of H. pylori infection is difficult, and 
successful regimens generally require two or more antibiotics 
coupled with a proton pump inhibitor.6 Eradication of the 
organism is the first therapeutic approach and constitutes 
a reliable long-term prophylaxis of peptic ulcer relapse, 
accelerating ulcer healing and reducing the rate of ulcer 
complications.4 However, the prevalence of multidrug-resistant 
strains, especially in developing countries,7 makes it obligatory 
to perform culture and antibiotic sensitivity for patients 
with persistent infection after failure of initial or repeated 
treatment.1
Antibiotic resistance is a major cause of treatment failure. 
Primary resistance against clarithromycin and metronidazole 
is common in many countries,5,8 while resistance to different 
antibiotics used as first-line treatment varies between countries 
and communities, and may change with time and geographical 
location.1 In South Africa, the regimen for treating H. pylori 
infection comprises amoxicillin, metronidazole, clarithromycin 
and doxycycline (personal communication) and  theoretically 
should demonstrate 85 - 95% efficacy.9
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Objectives. Helicobacter pylori-associated infection is common 
in South Africa, as in other developing countries. Antibiotic 
resistance is recognised as a major cause of treatment failure. 
We studied the susceptibility and resistance patterns of H. 
pylori to guide empiric treatment and prevent the emergence 
of resistance.
Methods. Two hundred H. pylori strains obtained from gastric 
biopsies of patients presenting with gastric-related morbidities 
attending Livingstone Hospital, Port Elizabeth, were evaluated 
for their susceptibility to seven antibiotics – metronidazole, 
clarithromycin, tetracycline, amoxicillin, gentamicin, 
ciprofloxacin and erythromycin. H. pylori was isolated 
following standard microbiology procedures, and susceptibility 
determined using the Kirby-Bauer disc diffusion and agar 
dilution methods. Comparisons of antimicrobial resistance 
rates with sex of the patients were determined using the chi-
square test; a p-value of <0.05 was considered significant.
Results. Marked susceptibility was observed for ciprofloxacin 
(100%) and amoxicillin (97.5%), and good activity for 
clarithromycin (80%) and gentamicin (72.5%). However, 
marked resistance (95.5%) was observed for metronidazole. 
The minimal inhibitory concentration (MIC) ranged from 
0.0625 µg/ml to 8 µg/ml. The lowest MIC, with a range of 
0.0625 - 1 µg/ml, was recorded for ciprofloxacin, while the 
highest (5 - 8 µg/ml) was noted for gentamicin.
Conclusion. Multidrug resistance was commonly encountered 
– a finding of clinical significance that calls for continuous 
surveillance of antibiograms to guide empiric treatment. 
We advocate the inclusion of ciprofloxacin in the treatment 
regimen of H. pylori infection in our study environment.
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We recently identified H. pylori isolates from patients 
presenting with gastric diseases in the Eastern Cape. The 
organism is associated with substantial morbidity and 
mortality.2 An increase in treatment failure is emerging because 
of growing resistance to currently used antibiotics and the fact 
that the antibiotic susceptibility patterns of micro-organisms 
change with time and geographical location.1 Consequently, 
it is imperative to evaluate current susceptibility/resistance 
patterns of H. pylori strains in the Eastern Cape province 
in particular and South Africa in general, especially as 
existing studies are few and outdated,10,11 to guide empirical 
treatment and prevent the emergence of further resistance. We 
investigated the susceptibility and resistance patterns of these 
isolates to seven different antibiotics.
Methods
Bacterial strains
Two hundred H. pylori strains were isolated from patients 
suffering from gastric diseases and referred to Livingstone 
Hospital, Port Elizabeth, for endoscopy. Biopsies were taken 
after informed consent. The study was approved by the 
institutional review board of the University of Fort Hare and 
the Eastern Cape Department of Health (Protocol number 
EcDoH-Res 0002).
The organism was isolated and identified as previously 
reported.1 Biopsies were homogenised under aseptic 
conditions in 0.2 g/l of cysteine and 20% glycerol in brain-
heart infusion broth and a loop full-plated primarily on freshly 
prepared Columbia agar base (Oxoid, Basingstoke, England) 
supplemented with 7% sheep’s blood (Oxoid, England) and 
Skirrow’s supplement (Oxoid, England); trimethoprim (2.5 
mg), vancomycin (5 mg), cefsulodin (2.5 mg), and amphotericin 
(2.5 mg) were also added to the medium. All plates were 
incubated at 37ºC for 3 - 5 days under micro-aerophilic 
conditions (5 - 6% O2, 10% CO2, 80 - 85% N2) (Anaerocult, 
Basingstoke, England). Isolates were identified based on colony 
morphology and positive oxidase, urease and catalase tests. 
A reference strain of H. pylori (NCTC 11638) was included as 
a positive control. Confirmed isolates were suspended in 20% 
glycerol and stored at –80ºC in a freezer (Sanyo, Japan) for 
future experiments.
Antibiotic susceptibility testing
Susceptibility testing to determine zones of inhibition and 
minimum inhibitory concentration (MIC) was by the disk 
diffusion (Kirby-Bauer) technique and agar dilution methods 
respectively, which conform to the standard of the Clinical and 
Laboratory Standard Institute (CLSI)12 with little modification.1 
Antibiotics usually indicated for triple therapy, namely 
metronidazole (5 µg), clarithromycin (15 µg), tetracycline (10 
µg), amoxicillin (10 µg), gentamicin (10 µg), ciprofloxacin (5 µg) 
and erythromycin (10 µg) (Mast Diagnostics, Bootle, England), 
were used. This selection was based on the current treatment 
regimen in South Africa (personal communication) and 
elsewhere.6 Brain-heart infusion (BHI) agar (Oxoid, England) 
containing 7% horse blood and H. pylori-selective supplement 
(Oxoid, England) was used. H. pylori control strain NCTC 11638 
was included in all the experiments to determine susceptibility 
or resistance.1 The zones of inhibition were interpreted as 
previously reported.1,13
For the MIC values, susceptibility for clarithromycin 
was interpreted according to the CLSI guideline.12 Since 
the CLSI has not designated breakpoints for H. pylori 
for all the antibiotics commonly used for treatment, the 
resistant breakpoint used for metronidazole, gentamicin 
and erythromycin was ≥8 µg/ml; ≥2 µg/ml was used for 
tetracycline, >1.0 µg/ml for clarithromycin, and ≥1.0 µg/ml for 
ciprofloxacin and amoxicillin.12,13
Statistical analysis
The Epi Info 2000 software package (Centers for Disease 
Control and Prevention, Atlanta, USA) was used for statistical 
analysis. Comparisons of antimicrobial resistance rates with the 
sex of the patients were determined using the chi-square test 
and a p-value of <0.05 was considered significant.
Results
Antimicrobial patterns
Of the 200 strains subjected to the antibiotics, 100% 
susceptibility was recorded for ciprofloxacin and 97.5% for 
amoxicillin. Marked resistance was noted for metronidazole 
95.5% (Table I).
Of the 200 strains tested, 67 (33.5%) were from males and 
133 (66.5%) from females. The prevalence of metronidazole 
resistance in females and males was 125/191 (65.44%) and 
66/191 (34.55%) respectively, while for erythromycin it was 
61/89 (68.53%) and 28/89 (31.46%) respectively (Fig. 1). 
There was a higher prevalence of resistant isolates in female 
compared with male patients, that did not reach statistical 
significance (p>0.05).
MIC determination
Of the 7 antibiotics, metronidazole showed no MIC within 
the susceptible breakpoint range. MIC values for the other 
antibiotics were 0.0625 - 1.0 µg/ml for ciprofloxacin, 0.125 - 1.0 
µg/ml for clarithromycin, 1.25 - 2.0 µg/ml for tetracycline, and 
2.5 - 5 µg/ml for amoxicillin (Table I).
Discussion
The resistance of H. pylori to antibiotic treatment regimens is a 
growing problem,14 and in several African countries is largely 
linked to misuse of antibiotics.1 Our results revealed marked 
antimicrobial susceptibility rates of 100% for ciprofloxacin, 
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and 97.5% for amoxicillin, in line with other investigators.6,15 
Hung et al.6 documented 94.3% susceptibility of their strains to 
ciprofloxacin, and Kohanteb et al.15 reported 95.3% for theirs. 
The latter authors also reported very high rates of amoxicillin 
susceptibility ranging from 79 - 99%. Although the rate of 
amoxicillin resistance is low in this study, and was absent for 
ciprofloxacin, resistance for both drugs has been demonstrated 
in different parts of the world.16
A similar study in western Nigeria documented 100% 
resistance by H. pylori strains to amoxicillin.7 We theorise 
that this could be related to the differences in local antibiotic 
prescription practices and use.2 H. pylori has been reported to 
lose the resistant phenotype to amoxicillin because of freezing 
and storage,14 which most probably occurred in the different 
studies; this may also help to explain the observed differences.1
Amoxicillin resistance is thought to develop because 
of structural alterations in the penicillin-binding protein, 
or changes in proteins involved in cell wall synthesis.17 
The possibility of bacterial strains acquiring resistance to 
amoxicillin is therefore strong. Colonisation of the stomach 
with β-lactam-resistant bacteria may lead to the transfer of 
amoxicillin-resistance to H. pylori.
Our isolates were 80% susceptible to clarithromycin, 72.5% 
to gentamicin, 67.5% to tetracycline and 55.5% to erythromycin. 
Similar results were found in Ethiopia, Cameroon and Kenya, 
reporting very good activity of these antibiotics against H. 
pylori isolates.1 Others, however, have reported resistance to 
clarithromycin.14 Although clarithromycin is an expensive 
macrolide, cross-resistance linked with the use of other less 
expensive macrolides may be responsible for this resistance, 
since it is less abused.14 However, clarithromycin-susceptible 
and resistant strains have been isolated from patients with no 
history of exposure to macrolides,18 which may suggest that 
administration of clarithromycin may select for the resistant 
strains and therefore must be guided by empirical treatment.
We observed very high resistance (95.5%) to metronidazole, 
similarly to a study in Nigeria (100% resistance).7 Metronidazole 
resistance has been reported in 10 - 50% of all adult patients 
infected with H. pylori in developed countries,19 and virtually 
all strains are resistant in the developing countries.14 The high 
prevalence of metronidazole resistance in developing countries 
has been linked to the frequent use of nitroimidazole 
derivatives for the treatment of protozoal infections and 
gynaecological problems.1,2,14 This resistance is thought to be 
mostly because of genetic mutations in the RdxA and FrxA 
genes.5
We found no significant difference (p<0.05) in the prevalence 
of antibiotic-resistant strains among females and males, 
although there was a remarkable difference in metronidazole 
resistance between the sexes, as seen in other studies.14 
However, the higher resistance observed with metronidazole 
in females may be related to its use in treating trichomoniasis 
and bacterial vaginosis, which is common in most developing 
countries.1,14
In our study, MIC values for the antibiotics that 
demonstrated susceptibility to the isolates were 0.125 - 1.0 
µg/ml for clarithromycin, 1.25 - 2.0 µg/ml for tetracycline, 
2.5 - 5.0 µg/ml for amoxicillin,; 5 - 8.0 µg/ml for gentamicin, 
2.5 - 5.0 µg/ml for erythromycin, and 0.625 - 1.0 µg/ml for 
ciprofloxacin. These values are similar to those found in other 
Table I. Antibiotic sensitivity results of H. pylori strains isolated from gastric biopsy specimens
               Antrum           Corpus         Antrum                  Corpus                Overall              Overall           MIC
Antibiotics             No sus (%)           No sus (%)         No res (%)       No res (%)  Sus (%)              Res (%)           µg/ml
Clarithromycin      87 (82.07)           73 (77.65)         19 (17.92)       21 (22.34)  160 (80)              40 (20)           0.125 - 1.0
Tetracycline           69 (66.34)           66 (68.75)         35 (33.65)       30 (31.25)  135 (67.5)             65 (32.5)           1.25 - 2.0
Amoxicillin           103 (98.09)           92 (96.84)         2 (1.90)       3 (3.15)  195 (97.5)             5 (2.5)           2.5 - 5.0
Metronidazole       6 (5.94)           3 (3.03)         95 (94.05)       96 (96.96)  9 (4.5)              191 (95.5)           >10
Gentamicin            84 (75.67)           61 (68.53)         27 (24.32)       28 (31.46)  145 (72.5)             55 (27.5)           5 - 8.0
Erythromycin        69 (64.48)           42 (45.16)         38 (35.51)       51 (54.83)  111 (55.5)              89 (44.5)           2.5 - 5.0
Ciprofloxacin         107 (100)           93 (100)         00 (0)       00 (0)   200 (100)              00 (0)           0.0625 - 1.0
Res = resistance; Sus = susceptibility. Zone diameter breakpoints for clarithromycin testing were <14 mm resistance (R) and ≥14 susceptible (S); for tetracycline and amoxicillin <16 mm 
(R) and ≥16 (S); for metronidazole testing <10 mm (R) and ≥10 (S); for ciprofloxacin <17 mm resistance (R) and ≥17 mm susceptible (S); for gentamicin <15 mm resistance (R) and ≥15 
susceptible (S); and for erythromycin testing <19 mm resistance (R) and ≥20 susceptible (S).1,13


Fig. 1. Prevalence of antibiotic-resistant isolates in males and females.

Fig. 1. Prevalence of antibiotic-resistant isolates in males and females.
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studies,14 and are in agreement with CLSI-approved quality 
control ranges for H. pylori.12,13
Conclusion
We commonly encountered multidrug resistance of clinical 
significance that calls for continuous surveillance of 
antibiograms to guide empirical treatment. We advocate the 
inclusion of ciprofloxacin in the treatment regimen of H. pylori 
infection in our study environment. Our results also indicate 
the need to establish baseline susceptibility data for empirical 
treatment of cases and the conducting of studies involving 
newer and broad-spectrum antibiotics to address resistance.
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